术前应用靶向药物治疗ALK阳性NSCLC患者的围手术期安全性分析
Mengying FAN, Cunwei QIN, Yifan FANG, Hao FU, Liang DAI, Yongbo YANG, Zhen LIANG, Hongchao XIONG, Wanpu YAN, Keneng CHEN · 2026
Read 术前应用靶向药物治疗ALK阳性NSCLC患者的围手术期安全性分析 by Mengying FAN, Cunwei QIN, Yifan FANG, Hao FU, Liang DAI, Yongbo YANG, Zhen LIANG, Hongchao XIONG, Wanpu YAN, Keneng CHEN (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13482754.txt.
Description
Mengying Fan and nine colleagues tested in 2026 whether pre-surgery targeted drugs are safe for ALK-positive lung cancer patients. ALK inhibitors anchor post-surgery care, yet evidence for their pre-surgery use, especially on surgical safety, was thin.
In 11 patients treated before surgery at one Beijing centre from 2021 to 2024, mostly non-smoking women with adenocarcinoma, objective response reached 81.8 percent and all completed keyhole or robot-assisted surgery. Major pathological response hit 45.5 percent and complete response 27.3 percent, with average surgery near 122 minutes and median blood loss of 74 mL. No deaths occurred over a median 30-month follow-up, though three patients relapsed, supporting pre-surgery use in this small cohort.
Catalog record
| CREATOR | Mengying FAN, Cunwei QIN, Yifan FANG, Hao FU, Liang DAI, Yongbo YANG, Zhen LIANG, Hongchao XIONG, Wanpu YAN, Keneng CHEN |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |